Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-08-20

Keros Therapeutics, Inc. (KROS)

CEO Jasbir Seehra was paid $2,540,204 in fiscal year 2025, ↓ down 59.5% from fiscal year 2024, the 16th percentile of its disclosed peer group (SEC filing 0001104659-26-046791 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,540,204 ↓
Jasbir Seehra total, FY2025
16th
CEO pay percentile vs peers
—
CEO-to-median pay ratio
93.61%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

KROS's next annual pay disclosure, estimated April 21, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Jasbir Seehra$700,000$0$1,426,280$0$398,125$0$15,799$2,540,204
President and Chief Executive Officer
Christopher Rovaldi578,9230871,20000025,9901,476,114
Former President and Chief Operating Officer
Keith Regnante470,3820464,6400164,850014,0001,113,872
Chief Financial Officer
Esther Cho459,1920464,6400161,000014,0001,098,832
Chief Legal Officer and Secretary

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Jasbir Seehra$2,540,204$6,273,192$8,932,076↓ −3,732,988
Christopher Rovaldi1,476,1146,975,4164,688,165↓ −5,499,302
Keith Regnante1,113,8722,292,1772,197,414↓ −1,178,305
Esther Cho1,098,832———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Keros Therapeutics, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper KROS reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the Keros Therapeutics, Inc. Peer Teardown Report

$2,540,204 Jasbir Seehra total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of August 20, 2026 · Source: 0001104659-26-046791 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for KROS

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
KROSon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order KROS

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against KROS
11 companies name KROS as a compensation peer

The list of companies that name KROS as a peer is temporarily unavailable — recheck shortly.

Get the Keros Therapeutics, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Esther ChoGeneral Counsel$1,098,832
Jasbir SeehraCEO$2,540,204
Christopher RovaldiPresident$1,476,114
Keith RegnanteCFO$1,113,872
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Alpna SethIndependent Director$238,535
Carl L. GordonFormer director (through FY2025)$232,535
Charles NewtonIndependent Director—
Jean-Jacques BienaimChair of the Board—
Julius KnowlesIndependent Director$239,035
Mary Ann GrayIndependent Director$247,535
Nima FarzanIndependent Director$239,035
Ran NussbaumFormer director (through FY2025)$136,614
Tomer KarivFormer director (through FY2025)$139,777
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Jean Jacques BienaimeDirector2026-05-15A1,000$11$10,580CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-03A7,43300Derivative, Class A CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-03A7,14200CommonForm 4 ↗
Nima FarzanDirector2026-06-03A7,43300Derivative, Class A CommonForm 4 ↗
Mary Ann GrayDirector2026-06-03A7,14200CommonForm 4 ↗
Alpna SethDirector2026-06-03A7,43300Derivative, Class A CommonForm 4 ↗
Julius KnowlesDirector2026-06-03A7,43300Derivative, Class A CommonForm 4 ↗
Julius KnowlesDirector2026-06-03A7,14200CommonForm 4 ↗
Nima FarzanDirector2026-06-03A7,14200CommonForm 4 ↗
Mary Ann GrayDirector2026-06-03A7,43300Derivative, Class A CommonForm 4 ↗
Alpna SethDirector2026-06-03A7,14200CommonForm 4 ↗
Alpna SethDirector2026-06-04D2,6251128,140CommonForm 4 ↗
Julius KnowlesDirector2026-06-04D2,6251128,166CommonForm 4 ↗
Nima FarzanDirector2026-06-04D2,6251128,166CommonForm 4 ↗
Charles NewtonDirector2026-06-11D550105,522CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-15A1,0001010,190CommonForm 4 ↗
Anne PrenerDirector2026-07-01A14,87000Derivative, Class A CommonForm 4 ↗
Anne PrenerDirector2026-07-01A13,78600CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-07-15A1,0001110,610CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-08-17A1,0001010,270CommonForm 4 ↗
Lorena Raquel LernerChief Scientific Officer2026-08-18D3,5681036,715CommonForm 4 ↗
Annita TaniniCorp. Controller & VP, Finance2026-08-18D1,2241012,595CommonForm 4 ↗
Esther ChoChief Legal Officer2026-08-18D4,4851046,151CommonForm 4 ↗
Charles NewtonDirector2026-08-18D551105,675CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Esther ChoOTHER—————$464,640
Keith RegnanteOTHER—————464,640
Jasbir SeehraOTHER—————1,426,280
Christopher RovaldiOTHER—————871,200
03b

Vehicle mix — grant-date fair value by award type

Grant-level vehicle detail not disclosed.

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Keith RegnanteOption22,50056.18—
Keith RegnanteOption12,50054.38—
Jasbir SeehraOption62,50054.38—
Esther ChoRSU44,000—895,840
Jasbir SeehraOption70,31356.18—
Jasbir SeehraOption10,31346.3—
Esther ChoOption28,12556.18—
Keith RegnanteOption3,12546.3—
Esther ChoOption15,62554.38—
Esther ChoOption1,56346.3—
Jasbir SeehraRSU90,500—1,842,580
Jasbir SeehraPSU90,500—1,842,580
Keith RegnanteRSU44,000—895,840
05

Incentive-plan design — the Compensation Discussion & Analysis

Attract, retain and motivate superior executive talent; Provide incentives that reward the achievement of performance goals that directly correlate to the enhancement of stockholder value, as well as to facilitate executive retention; and Align our executives interests with those of our stockholders through long-term incentives linked to specific performance.

CEO STI target (% of salary)65%
CEO LTI target (% of salary)—
Independent consultantAon (Human Capital Solutions practice)
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-0314,273,625974,0492,03893.61%Passed
20252025-06-0418,580,6184,166,083963,57181.68%Passed
20242024-05-3028,988,355183,2678,06699.34%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0393.61%a
20252025-06-0481.68%b
20242024-05-3099.34%c

a. Approved under the standard stated in the filing — “withheld votes will have no effect ​ ​ Under plurality voting, there are no abstentions ​ ​ No effect ​ ​ 2 ​ ​ Ratification of the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 ​ ​ "FOR" votes from the holders of a majority of shares present by remote communication or represented by proxy and entitled to vote on the subject matter ​ ​ Against ​ ​ Not applicable (1) ​ ​ 3 ​ ​ Advisory approval of the compensation of our named executive officers ​ ​ "FOR" votes from the holders of a majority of shares present by remote communication or represented by proxy and entitled to vote on the subject matter ​ ​ Against ​ ​ No effect ​ ​ (1) This proposal is considered to be a "routine" matter.”.

b. Approved under the standard stated in the filing — “withheld votes will have no effect ​ ​ Under plurality voting, there are no abstentions ​ ​ No effect ​ ​ 2 ​ ​ Ratification of the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025 ​ ​ "FOR" votes from the holders of a majority of shares present by remote communication or represented by proxy and entitled to vote on the subject matter ​ ​ Against ​ ​ Not applicable (1) ​ ​ 3 ​ ​ Advisory approval of the compensation of our named executive officers ​ ​ "FOR" votes from the holders of a majority of shares present by remote communication or represented by proxy and entitled to vote on the subject matter ​ ​ Against ​ ​ No effect ​ ​ (1) This proposal is considered to be a "routine" matter.”.

c. Approved under the standard stated in the filing — “Abstentions will have the same effect as "AGAINST" votes on Proposals 2, 3 and 4, and will have no effect on Proposal 1.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Jean-Jacques BienaiméIndependent · Board Chair · Nominating and Corporate Governance (Chair)$72,908$77,805$108,730$0$0$259,443
Mary Ann GrayIndependent · Audit (Chair) · Compensation61,00077,805108,73000247,535
Julius KnowlesIndependent · Audit · Compensation52,50077,805108,73000239,035
Nima FarzanIndependent · Audit · Compensation52,50077,805108,73000239,035
Alpna SethIndependent · Compensation (Chair)52,00077,805108,73000238,535
Carl L. GordonIndependent · Compensation · Departed during FY46,00077,805108,73000232,535
Tomer KarivIndependent · Nominating and Corporate Governance (Chair) · Departed during FY39,53879,22321,01600139,777
Ran NussbaumIndependent · Nominating and Corporate Governance · Departed during FY36,37579,22321,01600136,614
Jasbir SeehraEmployee director000—00
Charles NewtonIndependent · Audit · Compensation · Newly elected000000
09

Board fee structure and ownership guideline

Annual cash retainer$41,500
Annual equity retainer$150,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)17,000 / 14,000 / 10,000
Stock ownership guideline2x annual board retainer
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$412,821
Equity awards (grant-date value)$625,276
All other compensation$0
Total cost of the board$1,038,097

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Keros Therapeutics, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Keros Therapeutics, Inc..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Scholar Rock Holding Corporation2025David Hallal$637,500$22,518,500$7,624,988$452,293$33,300,927
2SpringWorks Therapeutics, Inc.2024Saqib Islam760,0007,899,7606,689,100798,00016,153,317
3Protagonist Therapeutics, Inc.2025Dinesh Patel715,5005,839,2045,618,010686,88012,871,506
4Crinetics Pharmaceuticals, Inc.2025R. Scott Struthers718,5003,280,5407,160,564462,35511,628,959
5Akero Therapeutics, Inc.2024Andrew Cheng686,0002,879,1556,489,100411,60010,465,855
6Geron Corporation2025Harout Semerjian321,53809,695,400203,00010,221,755
7Disc Medicine, Inc.2025John Quisel695,0004,285,8174,441,046554,2639,986,626
8IDEAYA Biosciences, Inc.2025Yujiro Hata700,00008,418,840378,0009,512,640
9Syndax Pharmaceuticals Inc.2025Michael Metzger754,3002,021,9653,454,360848,5887,089,213
10Replimune Group, Inc.2026Sushil Patel700,0003,376,0031,448,325315,0005,845,982
11Pliant Therapeutics, Inc.2025Bernard Coulie682,0001,810,2502,713,750204,6005,462,901
12Celldex Therapeutics, Inc.2025Anthony Marucci785,80404,027,59005,366,709
13KalVista Pharmaceuticals, Inc.2025Benjamin Palleiko477,2023,731,160005,094,999
14Kura Oncology, Inc.2025Troy Wilson700,00003,297,250630,0004,735,016
15Relay Therapeutics, Inc.2025Sanjiv Patel707,84603,513,900424,7084,646,454
16Rocket Pharmaceuticals, Inc.2025Gaurav Shah671,076806,7511,613,377403,0483,510,241
17Keros Therapeutics, Inc.2025Jasbir Seehra700,0001,426,2800398,1252,540,204
18Longboard Pharmaceuticals, Inc.2023Kevin Lind610,0000986,934442,8602,053,804
19Iovance Biotherapeutics, Inc.2025Frederick Vogt800,000759,3750312,0001,888,175
20Arcturus Therapeutics Holdings Inc.2025Joseph Payne750,0000941,00001,691,000

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Keros Therapeutics, Inc.87.5%RSU 50 · PSU 50NoAon (Human Capital Solutions practice)
Akero Therapeutics, Inc.100%not disclosednot disclosedPearl Meyer & Partners, LLC
Arcturus Therapeutics Holdings Inc.not disclosedOptions 100not disclosednot disclosed
Celldex Therapeutics, Inc.100%Options 100not disclosedAon (Human Capital Solutions practice, a division of Aon plc)
Crinetics Pharmaceuticals, Inc.not disclosedOptions 70 · RSU 30not disclosedPearl Meyer
Disc Medicine, Inc.145%RSU 50 · Options 50not disclosedPearl Meyer
Geron Corporation90%Options 75 · RSU 25not disclosedAon
IDEAYA Biosciences, Inc.90%Options 100not disclosedAon (Aon plc, Talent Solutions practice)
Iovance Biotherapeutics, Inc.60%not disclosedNoHaigh & Company
KalVista Pharmaceuticals, Inc.not disclosednot disclosedNoAon
Kura Oncology, Inc.150%not disclosedNoAlpine Rewards
Longboard Pharmaceuticals, Inc.not disclosedOption 100not disclosedFrederic W. Cook & Co.
Pliant Therapeutics, Inc.not disclosedOptions 67 · RSU 33not disclosedAlpine Rewards
Protagonist Therapeutics, Inc.160%Options 50 · RSU 50not disclosedAon Human Capital Solutions
Relay Therapeutics, Inc.100%Option 100not disclosedAon's Human Capital Solutions practice, a division of Aon plc
Replimune Group, Inc.not disclosednot disclosedNoPearl Meyer
Rocket Pharmaceuticals, Inc.not disclosednot disclosednot disclosedSemler Brossy
Scholar Rock Holding Corporationnot disclosednot disclosedNoPay Governance
SpringWorks Therapeutics, Inc.140%not disclosedYes — Relative Total Shareholder Return (TSR)Aon
Syndax Pharmaceuticals Inc.150%Options 34 · PSU 33 · RSU 33Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRsAon

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Keros Therapeutics, Inc. in fiscal 2025?
As disclosed, Jasbir Seehra (President and Chief Executive Officer) was the highest-paid executive at Keros Therapeutics, Inc. in fiscal 2025, with total compensation of $2,540,204.
How does Keros Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Jasbir Seehra's total compensation ranked at the 16th percentile of Keros Therapeutics, Inc.'s disclosed peer group.
How did shareholders vote on Keros Therapeutics, Inc.'s executive compensation?
As disclosed, 93.61% of shareholders supported Keros Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Keros Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Keros Therapeutics, Inc. reported total board compensation of $1,038,097 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Jasbir SeehraDEF 14A2026-04-220001104659-26-046791Section “Summary Compensation Table”. As printed: 2,540,204. Filing ↗machine: r1 · c41 · span 627980–627989
2Section 01, Christopher RovaldiDEF 14A2026-04-220001104659-26-046791Section “Summary Compensation Table”. As printed: 1,476,114. Filing ↗machine: r6 · c41 · span 649591–649600
3Section 01, Keith RegnanteDEF 14A2026-04-220001104659-26-046791Section “Summary Compensation Table”. As printed: 1,113,872. Filing ↗machine: r3 · c41 · span 636468–636477
4Section 01, Esther ChoDEF 14A2026-04-220001104659-26-046791Section “Summary Compensation Table”. As printed: 1,098,832. Filing ↗machine: r5 · c41 · span 644770–644779
5Section 03, Esther Cho OTHERDEF 14A2026-04-220001104659-26-046791Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t19 · r5 · c17 · span 642598–642605
6Section 03, Keith Regnante OTHERDEF 14A2026-04-220001104659-26-046791Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t19 · r3 · c17 · span 634216–634223
7Section 03, Jasbir Seehra OTHERDEF 14A2026-04-220001104659-26-046791Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t19 · r1 · c17 · span 625702–625711
8Section 03, Christopher Rovaldi OTHERDEF 14A2026-04-220001104659-26-046791Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t19 · r6 · c17 · span 647339–647346
9Section 07, pay ratio10-K2026-03-040001664710-26-000018Section “CEO Pay Ratio”. As printed: —. Filing ↗
10Section 08, Jean-Jacques BienaiméDEF 14A2026-04-220001104659-26-046791Section “Director Compensation”. As printed: 259,443. Filing ↗machine: span 946812–946819
11Section 08, Mary Ann GrayDEF 14A2026-04-220001104659-26-046791Section “Director Compensation”. As printed: 247,535. Filing ↗machine: t25 · r4 · c23 · span 954672–954679
12Section 08, Julius KnowlesDEF 14A2026-04-220001104659-26-046791Section “Director Compensation”. As printed: 239,035. Filing ↗machine: t25 · r6 · c23 · span 959951–959958
13Section 08, Nima FarzanDEF 14A2026-04-220001104659-26-046791Section “Director Compensation”. As printed: 239,035. Filing ↗machine: t25 · r2 · c23 · span 949390–949397
14Section 08, Alpna SethDEF 14A2026-04-220001104659-26-046791Section “Director Compensation”. As printed: 238,535. Filing ↗machine: t25 · r8 · c23 · span 965227–965234
15Section 08, Carl L. GordonDEF 14A2026-04-220001104659-26-046791Section “Director Compensation”. As printed: 232,535. Filing ↗machine: t25 · r3 · c23 · span 952092–952099
16Section 08, Tomer KarivDEF 14A2026-04-220001104659-26-046791Section “Director Compensation”. As printed: 139,777. Filing ↗machine: t25 · r5 · c23 · span 957370–957377
17Section 08, Ran NussbaumDEF 14A2026-04-220001104659-26-046791Section “Director Compensation”. As printed: 136,614. Filing ↗machine: t25 · r7 · c23 · span 962650–962657
18Section 08, Jasbir SeehraDEF 14A2026-04-220001104659-26-046791Section “Director Compensation”. As printed: 0. Filing ↗
19Section 08, Charles NewtonDEF 14A2026-04-220001104659-26-046791Section “Director Compensation”. As printed: 0. Filing ↗machine: t25 · r9 · c23 · span 967931–967938
20Section 02, Jean Jacques Bienaime 2026-05-15Form 42026-05-190001221590-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Jean Jacques Bienaime 2026-06-03Form 42026-06-050001221590-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Jean Jacques Bienaime 2026-06-03Form 42026-06-050001221590-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Nima Farzan 2026-06-03Form 42026-06-050001808296-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Mary Ann Gray 2026-06-03Form 42026-06-050001261974-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Alpna Seth 2026-06-03Form 42026-06-050001721020-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Julius Knowles 2026-06-03Form 42026-06-050001808365-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Julius Knowles 2026-06-03Form 42026-06-050001808365-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Nima Farzan 2026-06-03Form 42026-06-050001808296-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Mary Ann Gray 2026-06-03Form 42026-06-050001261974-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Alpna Seth 2026-06-03Form 42026-06-050001721020-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Alpna Seth 2026-06-04Form 42026-06-050001721020-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Julius Knowles 2026-06-04Form 42026-06-080001808365-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Nima Farzan 2026-06-04Form 42026-06-080001808296-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Charles Newton 2026-06-11Form 42026-06-150001866219-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Jean Jacques Bienaime 2026-06-15Form 42026-06-170001221590-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Anne Prener 2026-07-01Form 42026-07-060001797917-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Anne Prener 2026-07-01Form 42026-07-060001797917-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Jean Jacques Bienaime 2026-07-15Form 42026-07-170001221590-26-000023Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Jean Jacques Bienaime 2026-08-17Form 42026-08-190001221590-26-000025Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Lorena Raquel Lerner 2026-08-18Form 42026-08-200002081359-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Annita Tanini 2026-08-18Form 42026-08-200002146784-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Esther Cho 2026-08-18Form 42026-08-200002081460-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Charles Newton 2026-08-18Form 42026-08-200001866219-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
44Section 06, 2026 voteForm 8-K2026-06-030001664710-26-000034Item 5.07 · say-on-pay result. As reported: 93.61% (votes for as printed: 14,273,625.27). Filing ↗
45Section 06, 2025 voteForm 8-K2025-06-090001664710-25-000057Item 5.07 · say-on-pay result. As reported: 81.68% (votes for as printed: 18,580,618). Filing ↗
46Section 06, 2024 voteForm 8-K2024-05-300001664710-24-000045Item 5.07 · say-on-pay result. As reported: 99.34% (votes for as printed: 28,988,355). Filing ↗
47Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
48Section 09b board cost (computed)Computed——Cash 412,821 + equity 625,276 + all other 0 = 1,038,097, summed across the director compensation table rows.machine: formula: Σ = 1,038,097
49Scholar Rock Holding Corporation, Section 10b CEO totalDEF 14A2026-04-220001104659-26-046917CEO total compensation as printed in Scholar Rock Holding Corporation's own proxy. As printed: 33,300,927. Filing ↗machine: r1 · c47 · span 363867–363877
50SpringWorks Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-040001104659-25-032187CEO total compensation as printed in SpringWorks Therapeutics, Inc.'s own proxy. As printed: 16,153,317. Filing ↗machine: r1 · c47 · span 623184–623194
51Protagonist Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050429CEO total compensation as printed in Protagonist Therapeutics, Inc.'s own proxy. As printed: 12,871,506. Filing ↗machine: r1 · c47 · span 613195–613205
52Crinetics Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-290001658247-26-000030CEO total compensation as printed in Crinetics Pharmaceuticals, Inc.'s own proxy. As printed: 11,628,959. Filing ↗machine: r2 · c48 · span 589450–589460
53Akero Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-280000950170-25-058964CEO total compensation as printed in Akero Therapeutics, Inc.'s own proxy. As printed: 10,465,855. Filing ↗machine: t13 · r2 · c14 · span 492349–492359
54Geron Corporation, Section 10b CEO totalDEF 14A2026-04-070000886744-26-000024CEO total compensation as printed in Geron Corporation's own proxy. As printed: 10,221,755. Filing ↗machine: t118 · r6 · c23 · span 1062574–1062584
55Disc Medicine, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-187646CEO total compensation as printed in Disc Medicine, Inc.'s own proxy. As printed: 9,986,626. Filing ↗machine: r2 · c29 · span 696477–696486
56IDEAYA Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-290001193125-26-191501CEO total compensation as printed in IDEAYA Biosciences, Inc.'s own proxy. As printed: 9,512,640. Filing ↗machine: r2 · c14 · span 627310–627319
57Syndax Pharmaceuticals Inc., Section 10b CEO totalDEF 14A2026-04-300001193125-26-197859CEO total compensation as printed in Syndax Pharmaceuticals Inc.'s own proxy. As printed: 7,089,213. Filing ↗machine: span 936322–936331
58Replimune Group, Inc., Section 10b CEO totalDEF 14A2026-07-290001104659-26-087650CEO total compensation as printed in Replimune Group, Inc.'s own proxy. As printed: 5,845,982. Filing ↗machine: r1 · c41 · span 430765–430774
59Pliant Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-220001746473-26-000076CEO total compensation as printed in Pliant Therapeutics, Inc.'s own proxy. As printed: 5,462,901. Filing ↗machine: r2 · c48 · span 436933–436942
60Celldex Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-290001104659-26-050884CEO total compensation as printed in Celldex Therapeutics, Inc.'s own proxy. As printed: 5,366,709. Filing ↗machine: r1 · c54 · span 1024857–1024866
61KalVista Pharmaceuticals, Inc., Section 10b CEO total10-K/A2026-04-300001193125-26-197556CEO total compensation as printed in KalVista Pharmaceuticals, Inc.'s own proxy. As printed: 5,094,999. Filing ↗
62Kura Oncology, Inc., Section 10b CEO totalDEF 14A2026-04-100001193125-26-151335CEO total compensation as printed in Kura Oncology, Inc.'s own proxy. As printed: 4,735,016. Filing ↗machine: span 1018180–1018189
63Relay Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-186929CEO total compensation as printed in Relay Therapeutics, Inc.'s own proxy. As printed: 4,646,454. Filing ↗machine: r2 · c29 · span 660153–660162
64Rocket Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-060001140361-26-013335CEO total compensation as printed in Rocket Pharmaceuticals, Inc.'s own proxy. As printed: 3,510,241. Filing ↗machine: r2 · c24 · span 348766–348775
65Keros Therapeutics, Inc. (subject), Section 10b CEO totalDEF 14A2026-04-220001104659-26-046791CEO total compensation as printed in Keros Therapeutics, Inc.'s own proxy. As printed: 2,540,204. Filing ↗machine: r1 · c41 · span 627980–627989
66Longboard Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2024-04-120000950170-24-044023CEO total compensation as printed in Longboard Pharmaceuticals, Inc.'s own proxy. As printed: 2,053,804. Filing ↗machine: r2 · c22 · span 476646–476655
67Iovance Biotherapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050458CEO total compensation as printed in Iovance Biotherapeutics, Inc.'s own proxy. As printed: 1,888,175. Filing ↗machine: r6 · c16 · span 797910–797919
68Arcturus Therapeutics Holdings Inc., Section 10b CEO totalDEF 14A2026-04-240001193805-26-000507CEO total compensation as printed in Arcturus Therapeutics Holdings Inc.'s own proxy. As printed: 1,691,000. Filing ↗machine: t116 · r1 · c27 · span 296910–296919
69Section 10a, Geron Corporation reciprocityDEF 14A—0000886744-26-000024Geron Corporation's most recent proxy was read; its disclosed peer group does not include Keros Therapeutics, Inc.. Filing ↗
70Section 10a, Iovance Biotherapeutics, Inc. reciprocityDEF 14A—0001104659-26-050458Iovance Biotherapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Keros Therapeutics, Inc.. Filing ↗
71Section 10a, Kura Oncology, Inc. reciprocityDEF 14A—0001193125-26-151335Kura Oncology, Inc.'s most recent proxy was read; its disclosed peer group does not include Keros Therapeutics, Inc.. Filing ↗
72Section 10a, Pliant Therapeutics, Inc. reciprocityDEF 14A—0001746473-26-000076Pliant Therapeutics, Inc. names Keros Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
73Section 10a, Rocket Pharmaceuticals, Inc. reciprocityDEF 14A—0001140361-25-016656Rocket Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Keros Therapeutics, Inc.. Filing ↗
74Section 10a, Syndax Pharmaceuticals Inc. reciprocityDEF 14A—0001193125-26-197859Syndax Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Keros Therapeutics, Inc.. Filing ↗
75Section 10a, Arcturus Therapeutics Holdings Inc. reciprocityDEF 14A—0001193805-26-000507Arcturus Therapeutics Holdings Inc.'s most recent proxy was read; its disclosed peer group does not include Keros Therapeutics, Inc.. Filing ↗
76Section 10a, Protagonist Therapeutics, Inc. reciprocityDEF 14A—0001104659-26-050429Protagonist Therapeutics, Inc. names Keros Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
77Section 10a, Celldex Therapeutics, Inc. reciprocityDEF 14A—0001104659-26-050884Celldex Therapeutics, Inc. names Keros Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
78Section 10a, Disc Medicine, Inc. reciprocityDEF 14A—0001193125-26-187646Disc Medicine, Inc. names Keros Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
79Section 10a, Relay Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-186929Relay Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Keros Therapeutics, Inc.. Filing ↗
80Section 10a, Akero Therapeutics, Inc. reciprocityDEF 14A—0000950170-25-058964Akero Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Keros Therapeutics, Inc.. Filing ↗
81Section 10a, SpringWorks Therapeutics, Inc. reciprocityDEF 14A—0001104659-25-032187SpringWorks Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Keros Therapeutics, Inc.. Filing ↗
82Section 10a, Crinetics Pharmaceuticals, Inc. reciprocityDEF 14A—0001658247-26-000030Crinetics Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Keros Therapeutics, Inc.. Filing ↗
83Section 10a, IDEAYA Biosciences, Inc. reciprocityDEF 14A—0001193125-26-191501IDEAYA Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Keros Therapeutics, Inc.. Filing ↗
84Section 10a, Scholar Rock Holding Corporation reciprocityDEF 14A—0001104659-26-046917Scholar Rock Holding Corporation's most recent proxy was read; its disclosed peer group does not include Keros Therapeutics, Inc.. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the Keros Therapeutics, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
KROS Peer Teardown Report